Benaroya Research Institute at Virginia Mason

Seattle, Washington 98122

5 studies enrolling now · 34 studies all time

What they study most

AML, Abnormal Glucose Tolerance, Advanced Malignant Solid Neoplasm, Aging, Anal Carcinoma, Arthritis, Rheumatoid, Bladder Cancer, Brain Cancer, Brain Tumor, Breast Cancer, COVID-19, Cancer

Studies at this site

• SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes — Recruiting now
• Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) — Recruiting now
• Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis — Recruiting now
• Improving Uptake of Surveillance in Colorectal Cancer Survivors Through Navigation and Web Education — Recruiting now
• Study of Enhanced Programming Stimulation with the Enterra® Therapy System — Recruiting now
• A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT — Running, not enrolling
• Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals — Completed
• Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial — Running, not enrolling
• Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery — Stopped early
• A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) — Completed
• To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. — Completed
• Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer — Completed
• Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer — Completed
• Connect® Myeloid Disease Registry — Stopped early
• The Impact of Diabetes on REvascularization — Completed
• CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 — Completed
• Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C" — Completed
• The Circulating Cell-free Genome Atlas Study — Status unconfirmed
• Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C" — Completed
• Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. — Stopped early
• Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia — Completed
• Autologous Muscle Derived Cells for Female Urinary Sphincter Repair — Completed
• Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer — Status unconfirmed
• Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis — Completed
• Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection — Stopped early
• Cognition in the Study of Tamoxifen and Raloxifene — Completed
• Inducing Remission in Type 1 Diabetes With Alefacept — Stopped early
• Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis — Completed
• A Cooperative Clinical Study of Abatacept in Multiple Sclerosis — Completed
• T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus — Completed
• Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML) — Completed
• Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders — Stopped early
• Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus — Completed
• A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis — Stopped early